Maxibar

Barium sulfate, the active ingredient in Maxibar, is a contrast media presented as an oral preparation for oral use. It provides radiopaque contrast that coats the gastrointestinal tract, allowing clear visualization of the GI lumen during X‑ray and fluoroscopic examinations in patients requiring diagnostic imaging.

GNH USA supplies Maxibar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maxibar is a contrast agent used in gastrointestinal imaging procedures. It enhances radiographic and fluoroscopic visualization of the GI tract.

- Radiographic imaging of the gastrointestinal tract: Enables clear visualization of the GI lumen during barium swallow or barium enema studies. - Contrast enhancement for X‑ray examinations: Improves delineation of the esophagus, stomach, and intestines for diagnostic assessment. - Fluoroscopic studies of the GI tract: Provides real‑time radiopaque coating to assess motility and structural abnormalities. - Upper gastrointestinal series: Facilitates detailed imaging of the esophagus, stomach, and duodenum for detecting lesions or strictures.

Adverse reactions may occur following oral administration of barium sulfate. Most are mild and self‑limiting, but serious events are possible.

Common Side Effects: - Nausea: Transient feeling of queasiness after ingestion. - Abdominal cramping: Mild to moderate discomfort in the stomach area. - Constipation: Reduced bowel movements leading to hard stools. - Taste disturbance: Unpleasant metallic or chalky taste. - Mild diarrhea: Loose stools occurring shortly after dosing. - Vomiting: Infrequent episodes of expelling the preparation.

Serious or Rare Side Effects: - Allergic reaction: Rash, itching, or swelling indicating hypersensitivity. - Aspiration pneumonia: Inhalation of the suspension into the lungs. - Bowel obstruction: Worsening of pre‑existing obstruction due to the dense material. - Perforation risk: Increased danger in patients with known GI perforations. - Severe constipation leading to impaction: Requires medical intervention. - Anaphylactoid response: Rare systemic reaction requiring emergency care.

Prior to using Maxibar, clinicians should evaluate patient history and specific risk factors. - Assess for bowel obstruction: Avoid use in patients with known or suspected gastrointestinal blockage. - Evaluate for perforation risk: Do not administer to individuals with recent GI surgery or perforated ulcers. - Review allergy history: Exercise caution in patients with prior reactions to contrast agents. - Consider renal function: Although barium sulfate is not systemically absorbed, severe renal impairment may affect overall fluid balance. - Store at ambient temperature: Keep in the original container, protect from moisture and direct sunlight.

Barium sulfate can affect the absorption of certain oral medications and should be managed accordingly.

Major Interactions (Avoid): - Tetracycline antibiotics: Co‑administration can markedly reduce tetracycline absorption; avoid concurrent dosing. - Fluoroquinolone antibiotics: May impair absorption; separate administration by at least 2 hours.

Moderate Interactions (Monitor Closely): - Levothyroxine: Barium can decrease thyroid hormone absorption; schedule dosing at least 4 hours apart. - Iron supplements: Potential reduction in iron uptake; advise spacing of doses. - Bisphosphonates: May interfere with absorption; recommend separate dosing intervals.